

February 13, 2026

Company name: Alivexis, Inc.
Representative: S. Roy Kimura, Ph.D., CEO

Alivexis and OHARA Pharmaceutical Co., Ltd. to Collaborate on Selected Drug Targets

News – February 13, 2026 - Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura) is pleased to announce that it has entered into a Research Collaboration Agreement with OHARA Pharmaceutical Co., Ltd. ("OHARA") to identify small-molecule compounds for multiple targets selected by OHARA, leveraging Alivexis' drug discovery platform ModBind™ and related technologies.

Under this collaboration, Alivexis will apply its computational drug discovery platform, including ModBind™, to support the discovery of novel small-molecule candidates for multiple targets in the neuroscience field. In addition to in silico evaluations, Alivexis will provide research support, including structural analysis of compound–target interactions, and will work jointly with OHARA to establish experimental systems and perform compound synthesis, evaluation, and optimization.

In support of this drug discovery program, Alivexis will receive a one-time fee for the use of its computational drug discovery platform, research funding, and may be eligible to receive financial consideration, subject to the terms and conditions of the collaboration agreement.

About ModBind™.

ModBind™ is a proprietary physics-based simulation technology developed by Alivexis that enables high-speed, highly accurate prediction of absolute binding strength between small molecule compounds and target proteins, without the need for experimentally-derived biological activity data. Leveraging ModBind™ along with other platform technologies, we have already advanced five compounds to clinical candidate status. One program resulted in a licensing agreement with a Swiss company in June 2024, valued at approximately 42.5 billion yen, demonstrating the practical and commercial utility of our technology. In addition, we have conducted multiple joint research projects with pharmaceutical companies, with ModBind™ serving as the core technology in these collaborations.

In addition, in August 2025, we were selected for the third round of the "GENIAC (Generative AI Accelerator Challenge)" program, a project led by the Ministry of Economy, Trade and Industry (METI) and the New Energy and Industrial Technology Development



Organization (NEDO) which aims to strengthen domestic development capabilities in generative AI. By integrating ModBind™ with AI training, we aim to build and implement a generative AI foundation model for drug discovery that predicts the biological activity of small-molecule compounds with world-leading accuracy.

【CEO S. Roy Kimura's Comments】

“I am excited to announce the signing of our drug discovery collaboration with OHARA focused on the use of our proprietary and ground-breaking ModBind™ simulation technology to accelerate early drug discovery for a selected disease target. Through our collaboration, we look forward to gaining further validation of our technology while contributing to the discovery of novel clinical candidate compounds for diseases with significant unmet medical needs.”

About OHARA Pharmaceutical Co., Ltd.

Name: OHARA Pharmaceutical Co., Ltd.

Headquarter: 121-15 Toriino, Koka-cho, Koka-shi, Shiga 520-3403 Japan

Representative director: Seiji Ohara, Ph.D. CEO

Established: November 5, 1964

URL: <https://www.ohara-ch.co.jp>

Business Description: Manufacture and sale of orphan drugs, generic drugs, and active pharmaceutical ingredients.

About Alivexis, Inc.

Name: Alivexis, Inc.

Headquarter: Daiichi Hibiya Building 7F Shimbashi 1-18-21, Minato-ku, Tokyo 105-0004, Japan

Representative directors: S. Roy Kimura, Ph.D., CEO / Kazuki Ohno, Dr. Eng. COO

Established: August 8, 2016

URL: <https://alivexis.com>

Business Description: A network-based drug discovery company utilizing cutting-edge technologies.

<p>Contact Information Business Administration Division info@alivexis.com</p>
